The Fort Worth Press - Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

USD -
AED 3.672498
AFN 64.499323
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 918.000243
ARS 1552.197099
AUD 1.485244
AWG 1.8
AZN 1.701711
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.796601
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.43051
CDF 2294.000011
CHF 0.842715
CLF 0.025343
CLP 997.870447
CNY 6.66615
CNH 6.666703
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.25025
DJF 178.024567
DKK 6.816895
DOP 60.539085
DZD 137.180101
EGP 53.80403
ERN 15
ETB 164.079674
EUR 0.91201
FJD 2.2979
FKP 0.756582
GBP 0.75965
GEL 2.590382
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 74.000218
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.846125
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 335.719966
IDR 18245
ILS 3.25995
IMP 0.756582
INR 93.38725
IQD 1515.562185
IRR 1929053.504962
ISK 124.940161
JEP 0.756582
JMD 158.860526
JOD 0.709014
JPY 159.357016
KES 129.99979
KGS 87.449396
KHR 4078.347196
KMF 447.999493
KPW 900.00035
KRW 1332.070454
KWD 0.31168
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.095849
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.939838
MVR 15.401496
MWK 1733.487348
MXN 18.52445
MYR 4.115196
MZN 63.904398
NAD 16.912757
NGN 1351.38034
NIO 36.790956
NOK 9.68098
NPR 149.424033
NZD 1.81946
OMR 0.384476
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.661992
PKR 276.397058
PLN 4.022995
PYG 6228.540504
QAR 3.644326
RON 4.8758
RSD 107.282027
RUB 82.343634
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.850918
SDG 601.501965
SEK 10.15252
SGD 1.28964
SHP 0.757117
SLE 22.825034
SLL 20969.503664
SOS 571.283045
SRD 37.438
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.954497
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.44254
TTD 6.768777
TWD 32.947027
TZS 2652.502981
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501905
VND 25692.5
VUV 121.064676
WST 2.823281
XAF 598.239422
XAG 0.021814
XAU 0.000265110644
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 598.239422
XPF 108.472418
YER 236.549706
ZAR 17.17026
ZMK 9001.205977
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.077613
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)

A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS

Text size:

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the late-breaking abstract about the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the Phase 3 OnTarget trial, which indicates that crofelemer achieved significant results in this subgroup, has been accepted for a poster presentation on December 11, 2024 at the San Antonio Breast Cancer Symposium (SABCS). Patients with breast cancer accounted for the majority of participants in this unprecedented prophylactic clinical trial recently conducted by Napo for diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

"We are thrilled that this important abstract has been accepted for presentation at SABCS. A full study report on the breast cancer subgroup analysis will be presented at the meeting and is expected to be submitted to a peer-reviewed journal," said Lisa Conte, Jaguar's president and CEO. "The content of the abstract will serve as the cornerstone of the briefing package we plan to submit to the U.S. Food and Drug Administration to request a meeting to discuss possible pathways to make crofelemer available as efficiently as possible to breast cancer patients. Additional analyses of OnTarget prespecified subgroups are ongoing, and we believe data from additional analyses may result in future submissions to peer-reviewed forums."

The lead author of the abstract, and the National Principal Investigator of the OnTarget trial, is Pablo C. Okhuysen, MD, FACP, FIDSA, Professor, Department of Infectious Diseases, Infection Control and Employee Health at MD Anderson Cancer Center at the University of Texas in Houston. Other key authors of the abstract include Pravin Chaturvedi, PhD, Chair of Napo's Scientific Advisory Board (SAB) and Jaguar's Chief Scientific Officer; Napo SAB member Lee Schwartzberg, M.D., FACP, Chief of Medical Oncology at Renown Health in Reno, Nevada; Napo SAB member Eric Roeland, MD, FAAHPM, FASCO, Associate Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine, Oregon Health & Science University; Napo SAB member Stacey Tinianov, MPH, a Board Certified Patient Advocate; Napo SAB member Dr. Kelly Shanahan, a former clinician and a metastatic breast cancer patient who is now a full-time independent patient advocate; as well as two key advisors to Napo: Enoch Bortey and James Bolognese.

"It is an exciting time to be a part of the company's SAB," said Dr. Shanahan. "As a cancer patient, having options to manage the side effects of life saving drugs is very important. I believe studying crofelemer for the prophylaxis of CTD is very exciting. We cancer patients don't want to take a medication to deal with a side effect that in turn causes a different side effect."

A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation on December 11, 2024 at SABCS.

In addition to participating in both poster presentations with its SAB members at SABCS, and in alignment with Jaguar's core focus on patient comfort, dignity, and cancer supportive care in general, Napo will be hosting a gathering for patient advocates during SABCS as part of the company's ongoing patient engagement program.

Since 1977, SABCS has been the leading scientific conference for scientists, physicians, clinical investigators, breast care providers, and advocates seeking an exchange of new information in experimental biology, etiology, prevention, diagnosis, and therapy of premalignant breast disease and breast cancer. Based on attendance levels from 2023 SABCS, the symposium organizers anticipate more than 10,000 attendees for this year's event.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that a full study report for the OnTarget breast cancer results will be presented at SABCS 2024 and submitted to a peer-reviewed journal, Jaguar's expectation that the content of the abstract will serve as the cornerstone of the briefing package the company will submit to the U.S. Food and Drug Administration to request a meeting to discuss possible pathways to make crofelemer available as efficiently as possible to breast cancer patients, Jaguar's expectation that data from additional analyses of OnTarget prespecified subgroups may result in future submissions to peer-reviewed forums, and the expectation that Napo will host a gathering for patient advocates during SABCS as part of the company's ongoing patient engagement program. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

A.Williams--TFWP